Stockscreener 앱 받기
6.91
5.73%
-0.42
전일 마감가:
$7.33
열려 있는:
$7.3
하루 거래량:
22,552
Relative Volume:
0.41
시가총액:
$4.80M
수익:
$186.70K
순이익/손실:
$-18.82M
주가수익비율:
-0.2216
EPS:
-31.1883
순현금흐름:
$-14.79M
1주 성능:
-12.81%
1개월 성능:
-24.07%
6개월 성능:
-45.16%
1년 성능:
-72.20%
1일 변동 폭
$6.6005
$7.57
1주일 범위
$6.6005
$8.45
52주 변동 폭
$6.6005
$27.53
Envveno Medical Corp Stock (NVNO) Company Profile
명칭
Envveno Medical Corp
전화
949-261-2900
주소
70 DOPPLER, IRVINE
Compare NVNO vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
6.91 | 4.80M | 186.70K | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp 주식(NVNO)의 최신 뉴스
A severe vein condition has few effective treatments. A new video explores how many people have it. - Stock Titan
enVVeno Medical Corp (NASDAQ: NVNO) Activist Ownership Drops to Zero Following Complete Stake Sale - kalkinemedia.com
Two major holders fully exit enVVeno Medical Corp (NVNO) - Stock Titan
Braeden Lichti Files Exit Filing at enVVeno - marketscreener.com
Director Francis Duhay Sells 11 Shares of enVVeno Medical Corp (NVNO) - GuruFocus
enVVeno Medical (NVNO) director logs small preset stock sale - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares - Investing.com
Director at enVVeno (NASDAQ: NVNO) plans sale of 11 shares - Stock Titan
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - ACCESS Newswire
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - The Joplin Globe
A medical-device CEO's presentation is now online ahead of New York meetings - Stock Titan
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - ACCESS Newswire
EnVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - marketscreener.com
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - Barchart.com
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - The Joplin Globe
enVVeno Medical files prospectus to offer securities for up to $100 million - scanx.trade
enVVeno Medical (NASDAQ: NVNO) readies $100M in potential securities sales - Stock Titan
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet
NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - vinanet.vn
enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade
enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - Yahoo Finance
enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget
EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal
enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corp expected to post a loss of $4.69 a shareEarnings Preview - TradingView
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Income Statement - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineSaaS Earnings Trends - Vinanet
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchRSI Overbought Alerts - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchOpening Range Breakout - Vinanet
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineBanking Earnings Report - po-news-eg.net
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineProfit Guidance Range - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineEarnings Weakness Phase - vinanet.vn
NVNO Q3 2025 Earnings: Narrower Loss Than Expected as enVVeno Controls CostsDividend Cut Risk - vinanet.vn
Envveno Medical Corp (NVNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Envveno Medical Corp 주식 (NVNO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Duhay Francis | Director |
Sep 11 '26 |
Proposed Sale |
11.18 |
11 |
123 |
0 |
| Duhay Francis | Director |
Jun 11 '26 |
Sale |
10.30 |
140 |
1,443 |
2,362 |
| Duhay Francis | Director |
Jun 11 '26 |
Proposed Sale |
10.31 |
140 |
1,443 |
0 |
| Duhay Francis | Director |
Mar 12 '26 |
Sale |
11.52 |
140 |
1,613 |
2,502 |
| Duhay Francis | Director |
Mar 12 '26 |
Proposed Sale |
11.52 |
140 |
1,613 |
0 |
| Duhay Francis | Director |
Dec 11 '25 |
Sale |
0.36 |
4,900 |
1,742 |
92,544 |
2.72%
1.62%
자본화:
|
볼륨(24시간):